Ustekinumab is a newer biological treatment for psoriasis. This drug is still being reviewed by the FDA but has shown to be very effective in clinical trials. Ustekinumab targets interleukin 12 and interleukin 23. It can provide long-term relief from psoriasis.
The early results show that is can relieve the pain and inflammation rapidly and its effectiveness lasts several months. The drug will hopefully be approved for use in moderate or severe psoriasis. Ustekinumab is very similar to Embrel but appears to be more efficacious and long lasting.
The only negative is that the drug is going to cost a fortune when it finally does become available.
